



2 April 2020

## **Medicine Supply Alert Notice**

### **Staneke® (levodopa/carbidopa/entacapone) tablets - various strength**

**Priority: Level 2\***

**Valid until: various – see table below**

#### **Issue**

1. Teva have advised that there are supply issues impacting Staneke® tablets in various strengths as set out in the table below.

#### **Advice and actions**

2. For patients with insufficient supplies of Staneke® until the anticipated resupply date, clinicians should consider prescribing levodopa/carbidopa/entacapone tablets generically so that pharmacies can supply Sastravi® or Stalevo® tablet.

<b>Staneke® Presentation Affected</b>	<b>Out of Stock Date</b>	<b>Anticipated Resupply date</b>
<b>150mg/37.5mg/200mg tablets</b>		
Pack size 100	19/02/2020	Mid-June 2020
Pack size 30	16/02/2020	Mid-June 2020
<b>100mg/25mg/200mg tablets</b>		
Pack size 30	25/02/2020	End June 2020
<b>125mg/31.25mg/200mg tablets</b>		
Pack size 100	24/04/2020	End July 2020
Pack size 30	27/03/2020	Mid-July 2020

3. All other Staneke® presentations remain available during this time.
4. Supplies of Sastravi® or Stalevo® tablets, which are considered equivalent, continue to remain available (see supporting information below).

#### **Supporting Information**

5. UKMi in consultation with a specialist pharmacist have advised that in practice, medicines for Parkinson's disease are not mandated to be prescribed by brand, although some very brittle patients may wish to stay on a particular brand. In the event of a shortage, the maintenance of supply of the drug is more important than the brand; and switching of brands is preferable to changing a patient's regimen. When switching brands, patients should be reassured that they are receiving the same treatment and monitored for side effects/change in disease control. As these combination products are often part of complex regimens and can be confusing to patients in terms of availability of various strengths, patients should be counselled on any changes to avoid medication errors, especially for those on more than one strength of Staneke® tablets.

#### **Enquiries**

6. Any enquiries should be directed to [PharmacyTeam@gov.scot](mailto:PharmacyTeam@gov.scot)

